このエントリーをはてなブックマークに追加
ID 69578
フルテキストURL
fulltext.pdf 1.17 MB
著者
Ishiyama, Ken Department of Hematology, Kanazawa University Hospital
Yamazaki, Masahide Department of Internal Medicine, Keiju Medical Center
Maruyama, Hiroyuki Department of Hematology, Kanazawa University Hospital
Hosono, Naoko Department of Hematology and Oncology, University of Fukui Hospital
Yamaguchi, Hiroki Department of Hematology, Nippon Medical School
Asada, Noboru Department of Hematology and Oncology, Okayama University Hospital Kaken ID researchmap
Tanimoto, Kazuki Department of Hematology and Oncology, Japanese Red Cross Fukuoka Hospital
Sugiura, Hiroyuki Department of Hematology, Chugoku Central Hospital of Japan Mutual Aid Association of Public School Teachers
Usuki, Kensuke Department of Hematology, NTT Medical Center Tokyo
Yoshimura, Kenichi Department of Biostatistics and Health Data Science, Graduate School of Medical Science, Nagoya City University
Ogawa, Seishi Department of Pathology and Tumor Biology, Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University
Kanakura, Yuzuru Sumitomo Hospital
Matsumura, Itaru Department of Hematology and Rheumatology, Kindai University Faculty of Medicine
Akashi, Koichi Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences
Nakao, Shinji Department of Hematology, Kanazawa University Hospital
抄録
The efficacy of ciclosporin (CsA) to treat transfusion-independent non-severe aplastic anaemia (TI-NSAA) has not yet been systematically evaluated. We conducted a prospective trial in patients with TI-NSAA treated with CsA monotherapy. CsA (3.5 mg/kg/day) was administered to patients with TI-NSAA aged ≥16. The CsA dose was adjusted to maintain a blood CsA level of ≥600 ng/mL at 2 h post-administration. Blood cell counts were assessed after 8, 16 and 52 weeks of therapy. Thirty-two evaluable patients from 21 institutions were enrolled. The median age was 63.5 (range: 16–83) years. At 8 weeks, haematological improvement, with increases in haemoglobin (Hb) ≥1.5 g/dL (haematological improvement in erythrocytes [HI-E]) and platelet count ≥30 × 109/L (haematological improvement in platelets [HI-P]), was observed in 0/25 (0%) and 6/32 (19%) evaluable cases respectively. HI-E and HI-P occurred in 1/25 (4%) and 10/32 (31%) patients at 16 weeks, respectively, and at 52 weeks in 5/25 (20%) and 16/32 (50%) patients respectively. Nine grade 3 adverse events (AEs) occurred in six patients, but there were no grade ≥4 AEs. Ten of the 32 patients experienced grade 2 renal toxicity. Low-dose CsA is effective in TI-NSAA patients and demonstrates minimal renal toxicity. However, at least 16 weeks are necessary to adequately evaluate its efficacy.
キーワード
ciclosporin
prospective study
renal toxicity
transfusion-independent non-severe aplastic anaemia
発行日
2025-09-08
出版物タイトル
British Journal of Haematology
出版者
Wiley
ISSN
0007-1048
NCID
AA00574570
資料タイプ
学術雑誌論文
言語
英語
OAI-PMH Set
岡山大学
著作権者
© 2025 The Author(s).
論文のバージョン
publisher
PubMed ID
DOI
Web of Science KeyUT
関連URL
isVersionOf https://doi.org/10.1111/bjh.70144
ライセンス
http://creativecommons.org/licenses/by-nc-nd/4.0/
Citation
Ishiyama K, Yamazaki M, Maruyama H, Hosono N, Yamaguchi H, Asada N, et al. Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study. Br J Haematol. 2025; 00: 1–9. https://doi.org/10.1111/bjh.70144
助成情報
( 一般社団法人九州臨床研究支援センター / Clinical Research Support Center Kyushu )